trial

Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment

NCTId NCT00337350
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 20 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2011-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
20 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Triple
Start
2003-09
Primary completion
2011-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
rosiglitazone

Sponsors

Massachusetts General HospitalLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator
Stanley Medical Research InstituteCollaborator

Investigators

1
David C. Henderson, MDPrincipal Investigator

Sites

1 total
Boston, United States

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE4
Primary Completion Date
2011-01
Status
COMPLETED
relationships
The graph out of here
drug
rosiglitazone
drug
lead_sponsor
Massachusetts General Hospital
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
Insulin Resistance
indication
investigator
David C. Henderson, MD
person